Table 1.
Baseline characteristics of patients with NSCLC in 2015
| Total | Non-survivor | Survivor | p-value | |
|---|---|---|---|---|
| No. of patients | 2,098 | 1,446 (68.9) | 652 (31.1) | |
| Male sex | 1,464 (69.8) | 1,091 (75.4) | 373 (57.2) | < 0.001 |
| Age (yr) | 69.0 (60.0–75.0) | 70.0 (62.0–76.0) | 65.0 (57.0–72.0) | < 0.001 |
| Ever-smoker | 1,328 (63.3) | 976 (67.5) | 352 (54.0) | < 0.001 |
| BMI (kg/m 2 ) | 23.0 (22.2–24.1) | 22.9 (21.6–24.2) | 23.4 (23.1–23.8) | 0.402 |
| Symptoms | 2,062 | 1,419 | 643 | |
| Asymptomatic | 322 (15.6) | 127 (8.9) | 195 (30.3) | < 0.001 |
| Cough | 697 (33.8) | 548 (38.6) | 149 (23.2) | < 0.001 |
| Sputum | 406 (19.7) | 310 (21.8) | 96 (15.0) | < 0.001 |
| Dyspnea | 374 (18.1) | 320 (22.6) | 54 (8.4) | < 0.001 |
| Hoarseness | 47 (2.3) | 42 (3.0) | 5 (0.8) | 0.002 |
| Hemoptysis | 128 (6.2) | 100 (7.0) | 28 (4.4) | 0.020 |
| Weight loss | 116 (5.6) | 94 (6.6) | 22 (3.4) | 0.004 |
| Pain | 381 (18.5) | 320 (22.6) | 61 (9.5) | < 0.001 |
| Histopathology | 2,098 | 1,446 | 652 | |
| Adenocarcinoma | 1,308 (62.3) | 810 (56.0) | 498 (76.4) | < 0.001 |
| Squamous cell carcinoma | 662 (31.6) | 522 (36.1) | 140 (21.5) | < 0.001 |
| Others | 247 (11.8) | 208 (14.4) | 39 (6.0) | < 0.001 |
| Performance status | 1,550 | 1,029 | 521 | < 0.001 |
| 0–1 | 1,371 (88.5) | 862 (83.8) | 511 (98.1) | |
| 2–4 | 177 (11.4) | 167 (16.2) | 10 (1.9) | |
| Clinical stage of NSCLC | 1,818 | 1,243 | 575 | < 0.001 |
| I | 390 (21.5) | 91 (7.3) | 299 (52.0) | |
| II | 261 (14.4) | 122 (9.8) | 139 (24.2) | |
| III | 653 (35.9) | 559 (45.0) | 94 (16.3) | |
| IV | 514 (28.3) | 471 (37.9) | 43 (7.5) |
Values are presented as the number (%) or median (interquartile range). BMI, body mass index; NSCLC, non–small cell lung cancer.